NCT05477056

Quality Improvement PrecivityAD Clinician Survey (QUIP I)

Quality Improvement Survey I.0: A Retrospective Data Analysis of Clinician Survey Responses Following the Utilization of the PrecivityADTM Blood Test for the Detection of Alzheimer's Disease Pathology (QUIP I)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 366 (actual)
• Sponsor: C2N Diagnostics · Industry
• Sex: All
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

There is an important unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and early dementia. MCI impacts 12-18% of people in the United States over age 60 and is often an initial clinical sign of Alzheimer's disease (AD) (Alzheimer's Association, 2022). The PrecivityAD test is an analytically and clinically validated blood test that aids healthcare providers in the diagnosis of AD in patients with MCI and early-stage dementia. C2N has created a quality improvement (QI) survey to gather insight from clinicians as to the clinical effectiveness of the commercially available PrecivityAD™ test, which identifies whether a patient with signs and symptoms of cognitive decline is likely to have amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease.

Detailed description

By gathering feedback from healthcare providers on patient selection, intended use, and anticipated outcomes and continued or revised care plans as a result of the test report, C2N can better understand the impact of the test results on diagnosis and patient management.

Conditions

• Alzheimer Disease
• Mild Cognitive Impairment
• Dementia
• Cognitive Decline

Interventions

Type	Name	Description
OTHER	PrecivityAD blood test	Clinician Survey post receipt of PrecivityAD blood test result

Timeline

• Start date: 2021-03-01
• Primary completion: 2022-10-06
• Completion: 2022-10-06
• First posted: 2022-07-28
• Last updated: 2025-02-20

Locations

1 site across 1 country: United States